Aarti Drugs Share Price

Aarti Drugs

CMP as on 17-May-22 15:30

₹ 420.00
0.90 0.21%

Open

₹ 420.85

Turnover (lac)

₹ 507

Prev. Close

₹ 419.10

Day's Vol (shares)

₹ 1,20,786

Day's Range (₹)

₹ 419.00
₹ 427.65

CMP as on17-May-22 15:29

₹ 420.80
1.95 0.47%

Open

₹ 428.00

Turnover (lac)

₹ 128

Prev. Close

₹ 418.85

Day's Vol (shares)

₹ 4,881

Day's Range

₹ 418.50
₹ 428.00

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 02-May-2022 - -
Audited Results AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2022 ,inter alia, to consider and approve and take on record Audited Financial Results for the Quarter and year ended March 31, 2022. We wish to inform you that Board of Directors at its Meeting held on Monday, May 9, 2022, approved the Audited Financial Results of the Company (Standalone and Consolidated) for the Quarter and Year ended March 31, 2022. In this regards we enclose; i. Statement showing the Financial Results (Standalone and Consolidated), ii. Statement of Assets and Liabilities (Standalone and Consolidated), iii. Cash Flow Statement (Standalone and Consolidated) iv. Auditors Report on the Financial Results (Standalone and Consolidated), v. Declaration in respect of Audit reports with unmodified opinion for the Financial Year ended March 31, 2022 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that, based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors at its meeting held today appointed Prof. Bhaskar Narayan Thorat (DIN: 01293824) and CA Neha Rajen Gada (DIN: 01642373) as an Additional Directors in the category of an Independent Director of the Company with effect from May 9, 2022 for the period of three years subject to approval of the Shareholders of the Company. (As Per BSE Announcement dated on 09.05.2022)
Board Meeting - 25-Jan-2022 - -
AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2022 inter alia to consider and approve and take on record Audited Financial Results for the Quarter and Nine months ended December 31 2021 and consider and declare Interim dividend for the FY 2021-22 if any. We wish to inform you that Board of Directors of the Company at its Meeting held on Monday, January 31, 2022, has declared the Interim Dividend Rs. 1/- (Rupee One) (@10%) per Equity share for the financial year 2021-22. Please note that as per Regulation 42(1)(a) of the SEBI (LODR) Regulations, 2015, Thursday, February 10, 2022 has been fixed as Record Date for the purpose of payment of Interim Dividend. (As Per BSE Announcement Dated on 31.01.2022)
Board Meeting - 20-Oct-2021 - -
AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2021 ,inter alia, to consider and approve Audited Financial Results for the Quarter and Half year ended September 30, 2021. We wish to inform you that Board of Directors at its Meeting held on Wednesday, October 27, 2021, approved the Audited Standalone and Consolidated Financial Results for the Quarter and Half year ended September 30, 2021. Pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015 we enclose the following:- Audited Standalone and Consolidated Financial Results for the Quarter and Half year ended September 30, 2021. Standalone and Consolidated Statement of Assets and Liabilities. Standalone and Consolidated Cash Flow Statement. Auditors Report on Standalone and Consolidated Financial Results for the Quarter and Half year ended September 30, 2021. Further, please note that the Company has already made necessary arrangement to publish the same in the Newspapers as required under the SEBI (LODR) Regulations, 2015. We wish to inform you that Board of Directors at its Meeting held on Wednesday, October 27, 2021, approved the Audited Standalone and Consolidated Financial Results for the Quarter and Half year ended September 30, 2021. Pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015 we enclose the following:- Audited Standalone and Consolidated Financial Results for the Quarter and Half year ended September 30, 2021. Standalone and Consolidated Statement of Assets and Liabilities. Standalone and Consolidated Cash Flow Statement. Auditors Report on Standalone and Consolidated Financial Results for the Quarter and Half year ended September 30, 2021. Further, please note that the Company has already made necessary arrangement to publish the same in the Newspapers as required under the SEBI (LODR) Regulations, 2015. (As Per BSE announcement Dated on 27.10.2021)
Board Meeting - 20-Jul-2021 - -
AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2021 ,inter alia, to consider and approve This is to inform you that next Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, July 27, 2021 to consider, approve and take on record Audited Financial Results for the Quarter ended June 30, 2021. We wish to inform you that Board of Directors at its Meeting held on Tuesday, July 27, 2021, approved the Audited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2021. (As Per BSE Announcement dated on 27.07.2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity